How to buy Biomea Fusion stock | $11.74

Biomea Fusion Inc is a biotechnology business based in the US. Biomea Fusion shares (BMEA) are listed on the NASDAQ and all prices are listed in US Dollars. Biomea Fusion employs 20 staff and has a market cap (total outstanding shares value) of 0.00.

Biomea Fusion stock price (NASDAQ: BMEA)

Use our graph to track the performance of BMEA stocks over time.

Biomea Fusion shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$11.74
52-week range	$9.72 - $22.22
50-day moving average	$11.94
200-day moving average	$14.71
Wall St. target price	$26.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.23

Buy Biomea Fusion shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Biomea Fusion stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biomea Fusion price performance over time

Historical closes compared with the close of $11.74 from 2021-10-19

1 week (2021-10-13)	4.92%
1 month (2021-09-20)	13.43%
3 months (2021-07-20)	-13.93%
6 months (2021-04-20)	-30.08%

1 year (2020-10-16)	N/A
2 years (2019-10-16)	N/A
3 years (2018-10-16)	N/A
5 years (2016-10-16)	N/A

Biomea Fusion financials

Gross profit TTM	$0
Return on assets TTM	-10.6%
Return on equity TTM	-17.49%
Profit margin	0%
Book value	$6.97
Market capitalisation	$337.3 million

TTM: trailing 12 months

Shorting Biomea Fusion shares

There are currently 1.6 million Biomea Fusion shares held short by investors – that's known as Biomea Fusion's "short interest". This figure is 14% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Biomea Fusion shares can be evaluated.

Biomea Fusion's "short interest ratio" (SIR)

Biomea Fusion's "short interest ratio" (SIR) is the quantity of Biomea Fusion shares currently shorted divided by the average quantity of Biomea Fusion shares traded daily (recently around 78392.966507177). Biomea Fusion's SIR currently stands at 20.9. In other words for every 100,000 Biomea Fusion shares traded daily on the market, roughly 20900 shares are currently held short.

To gain some more context, you can compare Biomea Fusion's short interest ratio against those of similar companies.

• Vertex Pharmaceuticals Incorporated (VRTX.US): 3.72
• BioNTech (BNTX.US): 0.71
• bluebird bio (BLUE.US): 5.51

However Biomea Fusion's short interest can also be evaluated against the total number of Biomea Fusion shares, or, against the total number of tradable Biomea Fusion shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biomea Fusion's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Biomea Fusion shares in existence, roughly 60 shares are currently held short) or 0.1141% of the tradable shares (for every 100,000 tradable Biomea Fusion shares, roughly 114 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Biomea Fusion.

Find out more about how you can short Biomea Fusion stock.

Biomea Fusion share dividends

We're not expecting Biomea Fusion to pay a dividend over the next 12 months.

Biomea Fusion overview

Biomea Fusion, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is headquartered in Redwood City, California. .

Frequently asked questions

What percentage of Biomea Fusion is owned by insiders or institutions?
Currently 33.536% of Biomea Fusion shares are held by insiders and 58.679% by institutions. How many people work for Biomea Fusion?
Latest data suggests 20 work at Biomea Fusion. When does the fiscal year end for Biomea Fusion?
Biomea Fusion's fiscal year ends in December. Where is Biomea Fusion based?
Biomea Fusion's address is: Chamberlain Building, Redwood City, CA, United States, 94063 What is Biomea Fusion's ISIN number?
Biomea Fusion's international securities identification number is: US09077A1060